Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi/Regeneron and Amgen race ahead in PCSK9 inhibitors on positive early data

This article was originally published in Scrip

Executive Summary

Interest in inhibiting PCSK9 as a new therapeutic avenue in hypercholesterolaemia is gathering momentum on the back of promising clinical results reported this week showing reductions in LDL-cholesterol of over 70% with two potential drug offerings.

You may also be interested in...

Who’s Hired? Stada Names New Specialty Head

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Clue Faces Competitor Scrutiny On Entry Into Birth Control App Space

The US Food and Drug Administration has cleared Clue as the second app with a birth control indication to reach market -- but the first company on the scene questions whether it's as effective as theirs. 

Akorn Reviews Future Of Consumer Health Portfolio

US injectables specialist Akorn has begun to review strategic alternatives for its consumer health business, as the company looks at divesting some of its brands to increase financial flexibility and focus on its prescription generic and branded portfolio.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts